Veracyte Inc
VCYT
Company Profile
Business description
Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder). In addition, its Percepta Nasal Swab test is being run in CLIA labs in support of clinical studies.
Contact
6000 Shoreline Court
Suite 300
South San FranciscoCA94080
USAT: +1 650 243-6300
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
31 December 2025
Employees
824
Stocks News & Analysis
stocks
After earnings, is Uber stock a buy, a sell, or fairly valued?
With results exceeding management’s forecast for Q3, here’s what we think of Uber stock.
stocks
The largest share trading on the ASX remains materially overvalued
Profit barely budges on the most expensive bank in the world.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,079.40 | 38.00 | -0.42% |
| CAC 40 | 8,253.35 | 97.12 | 1.19% |
| DAX 40 | 24,376.43 | 288.37 | 1.20% |
| Dow JONES (US) | 48,287.29 | 359.33 | 0.75% |
| FTSE 100 | 9,916.07 | 16.47 | 0.17% |
| HKSE | 26,922.73 | 226.32 | 0.85% |
| NASDAQ | 23,327.65 | 140.65 | -0.60% |
| Nikkei 225 | 51,063.31 | 220.38 | 0.43% |
| NZX 50 Index | 13,671.73 | 67.18 | 0.49% |
| S&P 500 | 6,841.10 | 5.51 | -0.08% |
| S&P/ASX 200 | 8,799.50 | 36.50 | -0.41% |
| SSE Composite Index | 4,000.14 | 2.62 | -0.07% |